×
About 14,976 results
Three Leading National Public Health Organizations Ring The Alarm About All-time Highs Of STDs
http://www.ncsddc.org/three-leading-national-public-health-organizations-ring-the-alarm-about-all-time-highs-of-stds/

Oct 7th, 2019 - Data released this week by the Centers for Disease Control and Prevention (CDC) show STDs have surged for the fifth consecutive year, reaching an all-time high in the U.S. These dangerous trends in chlamydia, gonorrhea, and syphilis show no sign of slowing and affect millions of lives each year in the United States. Particularly worrisome is the emerging trend of newborn syphilis (congenital sy...

Genetics of Prostate Cancer (PDQ®)–Health Professional Version
https://www.cancer.gov/types/prostate/hp/prostate-genetics-pdq

Oct 4th, 2019 - This executive summary reviews the topics covered in this PDQ summary on the genetics of prostate cancer, with hyperlinks to detailed sections below that describe the evidence on each topic.

Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Niraparib for the Treatment of Metastatic Castration-Resistant Prostate Cancer
https://www.jnj.com/janssen-announces-u-s-fda-breakthrough-therapy-designation-granted-for-niraparib-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer

Oct 2nd, 2019 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for niraparib, an orally-administered poly ADP-ribose polymerase (PARP) inhibitor, for the treatment of patients with BRCA1/2 gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have received prior taxane che...

U.S. FDA Approves Supplemental New Drug Application (sNDA) for ERLEADA® (apalutamide) for the Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
https://www.janssen.com/us-fda-approves-supplemental-new-drug-application-snda-erleada-apalutamide-treatment-patients

Sep 16th, 2019 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved ERLEADA® (apalutamide) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).1 Today's approval follows FDA Priority Review Designation of the supplemental New Drug Application (sNDA) that was submitted in April 2019 and rev...

Urinary Incontinence in Women: Evaluation and Management
https://www.aafp.org/afp/2019/0915/p339.html
American Family Physician;

Sep 14th, 2019 - Urinary incontinence is a common problem among women worldwide, resulting in a substantial economic burden and decreased quality of life. The Women's Preventive Services Initiative is the only major organization that recommends annual screening for urinary incontinence in all women despite low to insufficient evidence regarding effectiveness and accuracy of methods. No other major organization ...

FDA approves darolutamide for non-metastatic castration-resistant prostate cancer
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-darolutamide-non-metastatic-castration-resistant-prostate-cancer

Jul 28th, 2019 - On July 30, 2019, the Food and Drug Administration approved darolutamide (NUBEQA, Bayer HealthCare Pharmaceuticals Inc.) for non-metastatic castration-resistant prostate cancer. Approval was based on ARAMIS (NCT02200614), a multicenter, double-blind, placebo-controlled clinical trial in 1,509 patients with non-metastatic castration resistant prostate cancer. Patients were randomized (2:1) to...

Bladder Cancer
https://www.cancer.org/cancer/bladder-cancer.html

Jul 28th, 2019 - "Whether you (or a loved one) are worried about developing bladder cancer, have just been diagnosed, are going through treatment, or are trying to stay well after treatment, this detailed guide can help you find the answers you need.

FDA grants orphan drug designation to Imfinzi for small cell lung cancer
https://www.healio.com/hematology-oncology/lung-cancer/news/online/%7B1a3bbdcb-d89d-41b5-ba26-640b5acd5ee1%7D/fda-grants-orphan-drug-designation-to-imfinzi-for-small-cell-lung-cancer

Jul 11th, 2019 - The FDA granted orphan drug designation to durvalumab for the treatment of small cell lung cancer. Durvalumab (Imfinzi, AstraZeneca) — a human monoclonal antibody that binds to PD-L1 — already is approved in the United States for treatment of patients with unresectable, stage III non-small cell lung cancer who underwent chemotherapy and radiation. The agent also is approved for previously tr...

Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2737101
JAMA Network Open;

Jul 2nd, 2019 - Question Is androgen deprivation therapy exposure associated with dementia among elderly patients with prostate cancer? Findings In this cohort study of 154 089 elderly men with prostate cancer, androgen deprivation therapy exposure was associated with subsequent diagnosis of Alzheimer disease or dementia over a follow-up period of at least 10 years. Meaning Clinicians must carefully w...

PSA Testing Use and Prostate Cancer Diagnostic Stage After the 2012 U.S. Preventive Services Task Force Guideline Changes
https://jnccn.org/view/journals/jnccn/17/7/article-p795.xml

Jun 30th, 2019 - Background: Most patients with prostate cancer are diagnosed with low-grade, localized disease and may not require definitive treatment. In 2012, the U.S. Preventive Services Task Force (USPSTF) recommended against prostate cancer screening to address overdetection and overtreatment. This study sought to determine the effect of guideline changes on prostate-specific antigen (PSA) screening and ...

Retrophin Announces FDA Approval of THIOLA® EC (tiopronin) 100mg and 300mg Tablets for the Treatment of Cystinuria
http://ir.retrophin.com/news-releases/news-release-details/retrophin-announces-fda-approval-thiolar-ec-tiopronin-100mg-and

Jun 27th, 2019 - Retrophin, Inc. (NASDAQ: RTRX) today announced that the U.S. Food and Drug Administration (FDA) has approved 100 mg and 300 mg tablets of THIOLA® EC (tiopronin), a new enteric-coated formulation of THIOLA® (tiopronin), to be used for the treatment of cystinuria, a rare inherited disorder that causes a buildup of cystine levels in the urine resulting in the formation of recurring cystine kidney...

Prostate Cancer in World Trade Center Responders Demonstrates Evidence of an Inflammatory Cascade
http://mcr.aacrjournals.org/content/early/2019/06/18/1541-7786.MCR-19-0115
Gong, Y. et. al.

Jun 19th, 2019 - An excess incidence of prostate cancer has been identified among World Trade Center (WTC) responders. In this study, we hypothesized that WTC dust, which contained carcinogens and tumor-promoting agents, could facilitate prostate cancer development by inducing DNA damage, promoting cell proliferation, and causing chronic inflammation. We compared expression of immunologic and inflammatory genes...

NICE Guidance – Prostate cancer: diagnosis and management
https://onlinelibrary.wiley.com/doi/10.1111/bju.14809

Jun 16th, 2019 - This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow‐up in primary care for people diagnosed with prostate cancer.

Testosterone - Lab Test
https://labtestsonline.org/tests/testosterone

Jun 4th, 2019 - Why Get Tested? To detect an abnormal testosterone level in males and females; in males, to help diagnose the cause of erectile dysfunction or the inability of your partner to get pregnant (infertility); in females, to help diagnose the cause of masculine physical features (virilization), infertility, or polycystic ovary syndrome (PCOS); in children, to help determine the cause of genitals tha...

FDA clears first diagnostic tests for extragenital testing for chlamydia and gonorrhea
https://www.fda.gov/news-events/press-announcements/fda-clears-first-diagnostic-tests-extragenital-testing-chlamydia-and-gonorrhea

May 22nd, 2019 - Today, the U.S. Food and Drug Administration cleared for marketing two tests that can detect the presence of the bacteria Chlamydia trachomatis and Neisseria gonorrhoeae, which cause the sexually-transmitted infections, respectively, chlamydia and gonorrhea, through diagnostic testing of extragenital specimens. The Aptima Combo 2 Assay and the Xpert CT/NG are the first devices cleared for extra...

Infertility Workup for the Women’s Health Specialist
https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Gynecologic-Practice/Infertility-Workup-for-the-Womens-Health-Specialist

May 22nd, 2019 - ABSTRACT: Infertility, defined as failure to achieve pregnancy within 12 months of unprotected intercourse or therapeutic donor insemination in women younger than 35 years or within 6 months in women older than 35 years, affects up to 15% of couples. An infertility evaluation may be offered to any patient who by definition has infertility or is at high risk of infertility. Women older than 35 y...

A four‐group urine risk classifier for predicting outcomes in patients with prostate cancer
https://onlinelibrary.wiley.com/doi/10.1111/bju.14811
BJU International; Connell, S. et. al.

May 19th, 2019 - To develop a risk classifier using urine‐derived extracellular vesicle (EV)‐RNA capable of providing diagnostic information on disease status prior to biopsy, and prognostic information for men on active surveillance (AS). Patients and Methods Post‐digital rectal examination urine‐derived EV‐RNA expression profiles (n = 535, multiple centres) were interrogated with a curated NanoString pane...

Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline
https://www.auanet.org/guidelines/recurrent-uti

Apr 30th, 2019 - Over the past few decades, our ability to diagnose, treat, and manage recurrent urinary tract infection (rUTI) long-term has evolved due to additional insights into the pathophysiology of rUTI, a new appreciation for the adverse effects of repetitive antimicrobial therapy (“collateral damage”), rising rates of bacterial antimicrobial resistance, and better reporting of the natural history and c...

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
https://jnccn.org/view/journals/jnccn/17/5/article-p479.xml
Journal of the National Comprehensive Cancer Network;

Apr 30th, 2019 - An estimated 174,650 new cases of prostate cancer will be diagnosed in 2019, accounting for 20% of new cancer cases in men.1 The age-adjusted death rates from prostate cancer have declined 51% from 1993 to 2016.1 Researchers have estimated that prostate cancer will account for 9.8% of male cancer deaths in 2018.1 Over the past several years, the incidence of prostate cancer has declined, likely...

Adjuvant and Salvage Radiotherapy after Prostatectomy: ASTRO/AUA Guideline
https://www.auanet.org/guidelines/prostate-cancer-adjuvant-and-salvage-radiotherapy-guideline
Thompson, I. et. al.

Apr 29th, 2019 - The purpose of this guideline is to provide direction to clinicians and patients regarding the use of radiotherapy after radical prostatectomy in the adjuvant or salvage setting. The strategies and approaches recommended in the guideline were derived from evidence-based and consensus-based processes. This document constitutes a clinical strategy; therefore, the most effective treatment approac...

Predict Prostate
https://prostate.predict.nhs.uk/

Mar 19th, 2019 - An individualised prognostic model for men newly diagnosed with non-metastatic prostate cancer

CTC AR-V7 Validated as Predictive Marker of Resistance to AR-Directed Therapy in mCRPC
https://www.onclive.com/web-exclusives/ctc-arv7-validated-as-predictive-marker-of-resistance-to-ardirected-therapy-in-mcrpc
Columbus, G.

Mar 12th, 2019 - Nuclear-localized androgen receptor splice variant 7 (AR-V7) protein in circulating tumor cells (CTCs) is a predictive marker of shorter progression-free and overall survival (OS) with antiandrogen therapy in patients with metastatic castration-resistant prostate cancer (mCRPC), according to results from the phase III PROPHECY trial that were published in the Journal of Clinical Oncology.

VENTANA PD-L1 (SP142) Assay - P160002/S009
https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm633972.htm

Mar 10th, 2019 - What is it? It is a test done in a laboratory using samples from triple negative breast cancer patients which doctors use to see if patients have programmed cell death ligand (PD-L1) in their cancer. When is it used? To help doctors decide whether atezolizumab is the best treatment choice for their patients. Atezolizumab is a drug that blocks PD-L1. Doctors use atezolizumab in combination wi...

Cancer incidence in the Agricultural Health Study after 20 years of follow-up
https://link.springer.com/article/10.1007%2Fs10552-019-01140-y
Cancer Causes & Control; Lerro, C. et. al.

Feb 24th, 2019 - To evaluate cancer incidence in the Agricultural Health Study (AHS), a cohort of private pesticide applicators, their spouses, and commercial applicators, based on 12,420 cancers, adding 5,989 cancers, and 9 years of follow-up since last evaluation. Overall AHS cancer incidence was lower than the general population (SIRprivate = 0.91, CI 0.89–0.93; SIRspouse = 0.89, CI 0.86–0.92; SIRcommercial ...

Impact of Incident Cancer on Short-Term Coronary Artery Disease–Related Healthcare Expenditures Among Medicare Beneficiaries
http://www.jnccn.org/content/17/2/149.full
Chopra, I. et. al.

Feb 19th, 2019 - Background: Healthcare spending for coronary artery disease (CAD)–related services is higher than for other chronic conditions. Diagnosis of incident cancer may impede management of CAD, thereby increasing the risk of CAD-related complications and associated healthcare expenditures. This study examined the relationship between incident cancer and CAD-related expenditures among elderly Medicare ...

Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG).
https://meetinglibrary.asco.org/record/170185/abstract

Feb 14th, 2019 - The PD-1 inhibitor pembro has durable antitumor activity in pts with metastatic urothelial carcinoma. Upregulation of the PD-1 pathway has been observed in BCG-resistant NMIBC, suggesting pembro may benefit. Efficacy and safety of pembro in pts with HR, BCG-unresponsive NMIBC was evaluated in the single-arm phase 2 KEYNOTE-057 study; updated results for pts with carcinoma in situ (CIS) with or ...

Genitourinary Cancers Symposium Poster Session A: Prostate Cancer
https://gucasym.org/program/poster-sessions/poster-session-a

Feb 13th, 2019 - Abstract 202: Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD.

Janssen Announces Preliminary Results from Phase 2 GALAHAD Study in Adults with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Pathway Defects (DRD)
https://www.janssen.com/janssen-announces-preliminary-results-phase-2-galahad-study-adults-metastatic-castration-resistant

Feb 13th, 2019 - The Janssen Pharmaceutical Companies of Johnson & Johnson will present today at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) early results from the ongoing Phase 2 GALAHAD study evaluating niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) and DNA-repair pathway defects (DRD)...

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
https://www.nejm.org/doi/full/10.1056/NEJMoa1815671?query=featured_home

Feb 13th, 2019 - Darolutamide is a structurally unique androgen-receptor antagonist that is under development for the treatment of prostate cancer. We evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resistant prostate cancer. Among men with nonmetastatic, castration-resistant prostate cancer, metastasis-free survival was significantly longer with da...

Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).
https://meetinglibrary.asco.org/record/169424/abstract

Feb 13th, 2019 - Immune checkpoint inhibitor monotherapy has shown limited clinical benefit in patients (pts) with prostate cancer, likely due to an immunologically “cold” tumor microenvironment. We report preplanned interim efficacy/safety for NIVO + IPI in pts with mCRPC from CheckMate 650.

Phase 3 study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial.
https://meetinglibrary.asco.org/record/170727/abstract

Feb 13th, 2019 - Background: ENZA, a potent androgen receptor inhibitor, has demonstrated benefit in men with metastatic and nonmetastatic castration-resistant prostate cancer (CRPC). Efficacy of ENZA with ADT in men with mHSPC is unknown. Methods: ARCHES is a multinational, double-blind, phase 3 study (NCT02677896). Patients (pts) with mHSPC were randomized 1:1 to ENZA (160 mg/day) + ADT or PBO + ADT, stratifi...

Phase II Trial Shows Novel, Radiolabeled PSMA-Targeted Treatment Provides High Response Rates in Men With Metastatic Prostate Cancer
https://www.asco.org/about-asco/press-center/news-releases/phase-ii-trial-shows-novel-radiolabeled-psma-targeted

Feb 10th, 2019 - A single-arm, phase II trial in men with PSMA-positive metastatic, castration-resistant prostate cancer (mCRPC) that progressed despite standard therapies, found that in the majority of men, the cancers were responsive to treatment with a novel, targeted radiation therapy called Lutetium-177 PSMA-617 (LuPSMA). This is the first prospective study of LuPSMA, part of a potential new class of treat...

Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015
https://jamanetwork.com/journals/jama/fullarticle/2724897?resultClick=1
Mahal, B. et. al.

Feb 10th, 2019 - Historically, most patients with low-risk prostate cancer (clinical category T1c-T2a, prostate-specific antigen level <10 ng/mL, and Gleason 6 disease) were treated with radical prostatectomy, while radiotherapy-based treatment was the favored approach for high-risk localized prostate cancer. However, conservative management of low-risk prostate cancer with active surveillance or watchful waiti...

Ureteral stent versus no ureteral stent for ureteroscopy in the management of renal and ureteral calculi
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012703.pub2/full
Ordonez, M. et. al.

Feb 5th, 2019 - Ureteroscopy combined with laser stone fragmentation and basketing is a common approach for managing renal and ureteral stones. This procedure is associated with some degree of ureteral trauma. Ureteral trauma may lead to swelling, ureteral obstruction, and flank pain and may require subsequent interventions such as hospital admission or secondary ureteral stent placement. To prevent such issue...

Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy
https://jamanetwork.com/journals/jamaoncology/fullarticle/2723273
Oudard, S.

Jan 30th, 2019 - Question: Is the combination of androgen-deprivation therapy plus docetaxel superior to androgen-deprivation therapy alone in the treatment of nonmetastatic prostate cancer in patients with increasing prostate-specific antigen levels after primary local therapy? Findings: In this phase 3 randomized clinical trial including 254 patients, there was no significant difference between treatments for...

Sangia Total PSA Test - P170037
https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm630197.htm

Jan 29th, 2019 - The Sangia Total Prostate Specific Antigen (PSA) Test consists of a Cassette Assembly and a Sample Collector. The Sangia Total PSA Test is used as an aid in the diagnosis of prostate cancer. This new test is the first point-of-care test that can deliver PSA results near where the patient is being evaluated, for example at the doctor's office, instead of waiting for lab analysis. The test can be...

Long-Term Effects of Finasteride on Prostate Cancer Mortality
https://www.nejm.org/doi/full/10.1056/NEJMc1809961
Goodman, P. et. al.

Jan 23rd, 2019 - The initial report on finasteride for prevention of prostate cancer documented a reduction in prostate cancers but a paradoxical increase in high-grade tumors. Prolonged follow-up and surveillance revealed that the number of deaths from prostate cancer was not increased by finasterid

Finasteride shows long-term safety, efficacy for prostate cancer prevention
https://www.healio.com/hematology-oncology/prostate-cancer/news/in-the-journals/%7B8121553c-91a8-49b8-8b73-279b81dbbbc8%7D/finasteride-shows-long-term-safety-efficacy-for-prostate-cancer-prevention

Jan 22nd, 2019 - Finasteride safely and effectively prevented prostate cancer, despite previous findings that suggested the drug increased the risk for high-grade disease, according long-term data published in The New England Journal of Medicine.

Prostate Cancer, Nutrition, and Dietary Supplements (PDQ®)–Health Professional Version
https://www.cancer.gov/about-cancer/treatment/cam/hp/prostate-supplements-pdq

Jan 13th, 2019 - This summary includes the history of research, reviews of laboratory and animal studies, and results of clinical trials on the following foods or dietary supplements: Calcium. Green tea. Lycopene. Modified citrus pectin. Pomegranate. Selenium. Soy. Vitamin D. Vitamin E. Multicomponent therapies. Other prostate health supplements.

Body Piercing Infections - StatPearls
https://www.ncbi.nlm.nih.gov/books/NBK537336/
Preslar, D.et al

Jan 5th, 2019 - Body piercings have become increasingly popular and a socially acceptable form of body modification. The most common site of piercings is the ear, with increasing popularity involving the mouth, nose, eyebrows, nipples, navel, and genitals. Localized cellulitis is the most common infectious complication resulting from body piercings. If not identified and treated accordingly these localized in...

Syphilis - StatPearls
https://www.ncbi.nlm.nih.gov/books/NBK534780/

Dec 28th, 2018 - Syphilis is a systemic, bacterial infection caused by the spirochete Treponema pallidum. Due to its many protean clinical manifestations, it has been named the “great imitator and mimicker.” The origin of syphilis has been controversial and under great debate and many theories have been postulated regarding this

Sub-castrate testosterone nadir and clinical outcomes in intermediate or high-risk localized prostate cancer
https://www.redjournal.org/article/S0360-3016(18)34080-X/pdf
Bryant, A. et. al.

Dec 9th, 2018 - Purpose It is unclear if additional serum testosterone suppression below the castrate threshold of 50 ng/dL improves clinical outcomes in patients with localized prostate cancer (PCa) undergoing definitive therapy. Methods We examined the association of sub-castrate testosterone nadir with PSA response and long-term clinical outcomes in 764 US veterans with intermediate- or high-risk localized ...

A Retrospective Study of Patients Undergoing Radical Cystectomy and Receiving Peri-Operative Naloxegol or Alvimopan: Comparison of Length of Stay
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298757/

Oct 11th, 2018 - Alvimopan is a μ-opioid receptor antagonist used in the post-operative period to decrease rates of post-operative ileus (POI) following radical cystectomy (RC) and thereby shorten length of stay (LOS). Naloxegol is a much less expensive drug of the same class that has yet to be studied for prevention of POI in the peri-operative period. The purpose of the current study is to evaluate the differ...

Antibiotic / Antimicrobial Resistance (AR / AMR) - Protecting Patients and Stopping Outbreaks
https://www.cdc.gov/drugresistance/protecting_patients.html

Sep 9th, 2018 - Your patients can get infections when receiving healthcare, called healthcare-associated infections (HAIs). HAIs are commonly caused by antibiotic-resistant pathogens (germs), which may lead to sepsis or death. People can also get antibiotic-resistant infections in their community, for example, gonorrhea, tuberculosis (TB), or foodborne infections. Take the following actions to help protect ...

Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline
http://ascopubs.org/doi/full/10.1200/JCO.18.00606
Bekelmanm J., et al

Sep 4th, 2018 - Purpose In April 2017, the American Urological Association, American Society for Radiation Oncology, and Society of Urologic Oncology released a joint evidence-based practice guideline on clinically localized prostate cancer. The American Society of Clinical Oncology (ASCO) has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other profession...

How to discuss STDs with patients
https://www.medicaleconomics.com/sexual-health/how-discuss-stds-patients
Dawson M.

May 20th, 2018 - Sexually transmitted diseases have reached unprecedented high levels, according to the CDC, with more than two million cases of chlamydia, gonorrhea, and syphilis, the highest number ever, reported in the U.S. in 2016. To make matters worse, not only are physicians not testing for STDs in accordance with CDC guidelines, STD testing rates have declined in the past few years, according to a repor...

Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement
https://jamanetwork.com/journals/jama/fullarticle/2680553
JAMA

May 7th, 2018 - Importance In the United States, the lifetime risk of being diagnosed with prostate cancer is approximately 11%, and the lifetime risk of dying of prostate cancer is 2.5%. The median age of death from prostate cancer is 80 years. Many men with prostate cancer never experience symptoms and, without screening, would never know they have the disease. African American men and men with a family his...

Digital Rectal Examination for Prostate Cancer Screening in Primary Care: A Systematic Review and Meta-Analysis
http://www.annfammed.org/content/16/2/149.full
Naji, L. et. al.

Feb 28th, 2018 - Although the digital rectal examination (DRE) is commonly performed to screen for prostate cancer, there is limited data to support its use in primary care. This review and meta-analysis aims to evaluate the diagnostic accuracy of DRE in screening for prostate cancer in primary care settings.

Antibiotic-Resistant Gonorrhea
https://www.cdc.gov/std/gonorrhea/arg/default.htm

Feb 14th, 2018 - Gonorrhea has progressively developed resistance to the antibiotic drugs prescribed to treat it. Following the spread of gonococcal fluoroquinolone resistance, the cephalosporin antibiotics have been the foundation of recommended treatment for gonorrhea. The emergence of cephalosporin-resistant gonorrhea would significantly complicate the ability of providers to treat gonorrhea successfully, si...

Syphilis- What Health Care Providers Can Do
https://www.cdc.gov/std/syphilis/CTAproviders.htm

Nov 7th, 2017 - Syphilis - STD Information from CDC. Facts, Statistics, Treatment, and Other Resources.